Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a large decrease in short interest in November. As of November 15th, there was short interest totalling 26,700 shares, a decrease of 11.3% from the October 31st total of 30,100 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS BPMUF remained flat at $52.83 during midday trading on Friday. The stock’s 50-day moving average price is $52.39 and its two-hundred day moving average price is $49.90. Basilea Pharmaceutica has a 12 month low of $38.60 and a 12 month high of $52.83.
Analysts Set New Price Targets
Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- How to Use Stock Screeners to Find Stocks
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- What is Put Option Volume?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.